Walden University
NURS6630 / NURS 6630: Psychopharmacology
Latest Final Exam – 2026/2027
50 Questions and Verified Correct Answers | A-Graded | Newest Version
Neurobiology • Antidepressants • Antipsychotics • Mood Stabilizers • Anxiolytics • Stimulants • Drug Interactions
Section 1: Neurobiology and Receptor Pharmacology (Questions 1–10)
Q1. A patient is started on fluoxetine (Prozac) for major depressive disorder. The PMHNP
understands that the therapeutic effect of SSRIs is primarily due to:
A. Blocking dopamine D2 receptors in the mesolimbic pathway
B. Inhibiting the reuptake of serotonin at the presynaptic neuron, increasing serotonin availability in the
synaptic cleft ✓
C. Blocking acetylcholinesterase to increase cholinergic neurotransmission
D. Enhancing GABA-A receptor activity to produce calming effects
Correct Answer: B
Rationale: SSRIs (Selective Serotonin Reuptake Inhibitors) work by selectively blocking the serotonin transporter
(SERT) on the presynaptic neuron, preventing serotonin reuptake and increasing its concentration in the synaptic
cleft. This enhanced serotonergic neurotransmission is responsible for their antidepressant, anxiolytic, and anti-OCD
effects. Option A describes the mechanism of first-generation antipsychotics. Option C describes
acetylcholinesterase inhibitors used for Alzheimer's disease (e.g., donepezil). Option D describes benzodiazepines
and barbiturates.
Q2. A PMHNP is educating a nursing student about the dopamine hypothesis of schizophrenia.
Which statement BEST explains the current understanding of dopamine dysregulation in
schizophrenia?
A. There is global dopamine excess throughout all brain regions
B. Hyperactivity of dopamine in the mesolimbic pathway causes positive symptoms, while hypoactivity
in the mesocortical pathway causes negative and cognitive symptoms ✓
C. Schizophrenia is caused solely by serotonin deficiency, not dopamine dysregulation
D. Dopamine excess in the nigrostriatal pathway is responsible for both positive and negative symptoms
Correct Answer: B
Rationale: The dopamine hypothesis has evolved to recognize regional specificity: mesolimbic dopamine
hyperactivity (D2 receptor hypersensitivity) is associated with positive symptoms such as hallucinations and
delusions, while mesocortical dopamine hypoactivity (D1 receptor hypofunction) correlates with negative symptoms
(blunted affect, alogia, avolition) and cognitive impairments. The nigrostriatal pathway (dopamine deficiency) is
associated with extrapyramidal side effects from antipsychotics, not symptom generation. Modern atypical
antipsychotics target multiple neurotransmitter systems including serotonin to address this complexity.
Q3. Which receptor mechanism best explains the weight gain commonly observed with
olanzapine (Zyprexa)?
A. Dopamine D2 receptor blockade in the striatum
B. Serotonin 5-HT2A receptor blockade in cortical regions
, C. Histamine H1 receptor blockade combined with muscarinic M3 receptor antagonism, which impairs
insulin secretion and increases appetite ✓
D. Alpha-1 adrenergic receptor blockade causing fluid retention
Correct Answer: C
Rationale: Olanzapine has high affinity for histamine H1 receptors (causing sedation and appetite stimulation) and
muscarinic M3 receptors on pancreatic beta cells (impairing glucose-stimulated insulin secretion and contributing to
metabolic syndrome). Together, these mechanisms drive significant weight gain and metabolic dysregulation.
Dopamine D2 blockade causes EPS. Serotonin 5-HT2A blockade improves negative symptoms and reduces EPS
risk. Alpha-1 blockade causes orthostatic hypotension. Understanding receptor binding profiles helps predict side
effects for all antipsychotics.
Q4. The PMHNP is reviewing the pharmacodynamics of buspirone (Buspar) with a patient. The
mechanism of action that distinguishes buspirone from benzodiazepines is:
A. Buspirone enhances GABA-A receptor chloride channel conductance
B. Buspirone is a partial agonist at serotonin 5-HT1A receptors and a weak D2 receptor antagonist — it
has no activity at GABA receptors and lacks abuse potential ✓
C. Buspirone blocks both serotonin and norepinephrine reuptake transporters
D. Buspirone directly inhibits cortisol synthesis to reduce anxiety
Correct Answer: B
Rationale: Buspirone's unique mechanism involves partial agonism at presynaptic serotonin 5-HT1A autoreceptors
(reducing serotonin release to modulate anxiety) and some D2 receptor antagonism. Unlike benzodiazepines,
buspirone has no GABA activity, no cross-tolerance with benzodiazepines, no abuse/dependence potential, no
sedation, and requires 2–4 weeks for full anxiolytic effect. It is preferred for patients with substance use history.
Option A describes benzodiazepines. Option C describes SNRIs. These distinctions are essential for appropriate
anxiolytic selection.
Q5. A patient taking a monoamine oxidase inhibitor (MAOI) for treatment-resistant depression
eats aged cheese at a restaurant. Which receptor/enzyme interaction explains the potentially
life-threatening hypertensive crisis that may follow?
A. Tyramine activates serotonin receptors, causing vasodilation and hypotension
B. Tyramine, normally metabolized by intestinal and hepatic MAO, accumulates when MAO is inhibited
and acts as an indirect sympathomimetic — releasing large amounts of norepinephrine from presynaptic
terminals causing severe hypertension ✓
C. MAOI inhibition of acetylcholinesterase causes acetylcholine excess and cholinergic crisis
D. Tyramine directly stimulates dopamine D1 receptors causing cerebral vasoconstriction
Correct Answer: B
Rationale: Tyramine (present in aged cheeses, cured meats, fermented foods) is normally degraded by monoamine
oxidase (MAO-A) in the gut and liver. When MAO is inhibited by an MAOI, tyramine enters systemic circulation,
enters adrenergic neurons, and displaces norepinephrine from vesicular stores — flooding the synapse with
norepinephrine. This 'tyramine pressor response' can cause severe hypertensive crisis, potentially leading to
intracranial hemorrhage or stroke. PMHNPs must educate patients on strict dietary restrictions when prescribing
MAOIs (phenelzine, tranylcypromine, isocarboxazid) and the tyramine-free diet.
Q6. A PMHNP understands that the 'therapeutic window' concept is MOST clinically relevant
when managing which medication?
A. Sertraline (Zoloft) for major depressive disorder
B. Lithium for bipolar disorder — toxicity occurs just above therapeutic levels ✓
C. Alprazolam (Xanax) for panic disorder
D. Aripiprazole (Abilify) for schizophrenia
Correct Answer: B
Rationale: Lithium has one of the narrowest therapeutic windows in psychiatry — therapeutic serum levels are 0.6–
1.2 mEq/L (acute mania: up to 1.5 mEq/L), while toxicity begins near 1.5–2.0 mEq/L and becomes life-threatening
above 2.0 mEq/L. Toxic symptoms include coarse tremor, ataxia, confusion, seizures, cardiac arrhythmias, and renal
failure. Regular serum level monitoring is mandatory. SSRIs, benzodiazepines, and atypical antipsychotics have
, much wider safety margins and do not require the same intensity of plasma level monitoring. The narrow therapeutic
index requires PMHNPs to educate patients on hydration, sodium intake, and drug interactions.
Q7. Which neurotransmitter system is the PRIMARY target of medications used to treat
attention-deficit/hyperactivity disorder (ADHD)?
A. GABAergic system — stimulant medications enhance inhibitory neurotransmission
B. Catecholamine systems (dopamine and norepinephrine) in prefrontal cortex circuits — stimulants
increase dopamine and norepinephrine signaling, improving attention, working memory, and inhibitory
control ✓
C. Serotonergic system — SSRIs are the first-line treatment for ADHD
D. Cholinergic system — acetylcholinesterase inhibitors improve attention span
Correct Answer: B
Rationale: ADHD involves hypoactivation of prefrontal cortex (PFC) dopaminergic and noradrenergic circuits
responsible for executive function, working memory, and inhibitory control. Stimulants (methylphenidate,
amphetamines) primarily block dopamine/norepinephrine reuptake transporters (DAT/NET), increasing
catecholamine signaling in PFC. Non-stimulants for ADHD include atomoxetine (selective NET inhibitor), viloxazine
(NET reuptake inhibitor), guanfacine and clonidine (alpha-2A agonists — strengthen PFC connectivity). SSRIs and
cholinesterase inhibitors are not first-line ADHD treatments.
Q8. A patient on clozapine (Clozaril) for treatment-resistant schizophrenia is found
unresponsive with a temperature of 104°F, muscle rigidity, and altered consciousness. The
PMHNP recognizes this presentation as consistent with:
A. Serotonin syndrome — treat with cyproheptadine
B. Neuroleptic malignant syndrome (NMS) — a dopamine receptor blockade emergency requiring
immediate discontinuation of the antipsychotic and supportive care including dantrolene ✓
C. Anticholinergic toxidrome — treat with physostigmine
D. Malignant hyperthermia from anesthesia — treat with dantrolene and cooling
Correct Answer: B
Rationale: Neuroleptic Malignant Syndrome (NMS) is a rare but life-threatening idiosyncratic reaction to dopamine
antagonists (antipsychotics, metoclopramide). The classic tetrad is: hyperthermia, severe muscle rigidity (lead pipe
rigidity), autonomic instability (tachycardia, labile blood pressure, diaphoresis), and altered consciousness.
Laboratory findings include elevated CPK, leukocytosis, and myoglobinuria. Treatment: immediately discontinue the
offending agent, supportive care, dantrolene (muscle relaxant), bromocriptine (dopamine agonist). NMS differs from
serotonin syndrome (clonus, hyperreflexia, GI symptoms) and anticholinergic toxidrome (dry/flushed/hot, no rigidity).
Q9. A PMHNP is explaining the difference between 'tolerance' and 'dependence' to a patient
being prescribed a benzodiazepine. Which statement BEST reflects current pharmacological
understanding?
A. Tolerance and physical dependence are the same as addiction and indicate the patient has substance use
disorder
B. Tolerance (decreasing effect with repeated dosing) and physical dependence (physiological
adaptation requiring the drug to prevent withdrawal) can develop with prescribed benzodiazepines —
these are expected pharmacological phenomena distinct from addiction (compulsive use despite harm)
✓
C. Tolerance only develops with illicit benzodiazepines, not with prescribed doses
D. Physical dependence means the patient should abruptly stop the medication to prevent further dependence
Correct Answer: B
Rationale: Tolerance and physical dependence are expected pharmacological consequences of regular
benzodiazepine use at prescribed doses. Tolerance results from GABA-A receptor downregulation and decreased
sensitivity. Physical dependence means abrupt discontinuation causes withdrawal symptoms (anxiety, insomnia,
tremor, seizures — potentially life-threatening). These phenomena are distinct from addiction (SUD), which involves
compulsive drug-seeking behavior despite negative consequences. PMHNPs must educate patients clearly, taper
benzodiazepines slowly (10-25% per week) to prevent withdrawal seizures, and assess for SUD risk factors before
prescribing.
NURS6630 / NURS 6630: Psychopharmacology
Latest Final Exam – 2026/2027
50 Questions and Verified Correct Answers | A-Graded | Newest Version
Neurobiology • Antidepressants • Antipsychotics • Mood Stabilizers • Anxiolytics • Stimulants • Drug Interactions
Section 1: Neurobiology and Receptor Pharmacology (Questions 1–10)
Q1. A patient is started on fluoxetine (Prozac) for major depressive disorder. The PMHNP
understands that the therapeutic effect of SSRIs is primarily due to:
A. Blocking dopamine D2 receptors in the mesolimbic pathway
B. Inhibiting the reuptake of serotonin at the presynaptic neuron, increasing serotonin availability in the
synaptic cleft ✓
C. Blocking acetylcholinesterase to increase cholinergic neurotransmission
D. Enhancing GABA-A receptor activity to produce calming effects
Correct Answer: B
Rationale: SSRIs (Selective Serotonin Reuptake Inhibitors) work by selectively blocking the serotonin transporter
(SERT) on the presynaptic neuron, preventing serotonin reuptake and increasing its concentration in the synaptic
cleft. This enhanced serotonergic neurotransmission is responsible for their antidepressant, anxiolytic, and anti-OCD
effects. Option A describes the mechanism of first-generation antipsychotics. Option C describes
acetylcholinesterase inhibitors used for Alzheimer's disease (e.g., donepezil). Option D describes benzodiazepines
and barbiturates.
Q2. A PMHNP is educating a nursing student about the dopamine hypothesis of schizophrenia.
Which statement BEST explains the current understanding of dopamine dysregulation in
schizophrenia?
A. There is global dopamine excess throughout all brain regions
B. Hyperactivity of dopamine in the mesolimbic pathway causes positive symptoms, while hypoactivity
in the mesocortical pathway causes negative and cognitive symptoms ✓
C. Schizophrenia is caused solely by serotonin deficiency, not dopamine dysregulation
D. Dopamine excess in the nigrostriatal pathway is responsible for both positive and negative symptoms
Correct Answer: B
Rationale: The dopamine hypothesis has evolved to recognize regional specificity: mesolimbic dopamine
hyperactivity (D2 receptor hypersensitivity) is associated with positive symptoms such as hallucinations and
delusions, while mesocortical dopamine hypoactivity (D1 receptor hypofunction) correlates with negative symptoms
(blunted affect, alogia, avolition) and cognitive impairments. The nigrostriatal pathway (dopamine deficiency) is
associated with extrapyramidal side effects from antipsychotics, not symptom generation. Modern atypical
antipsychotics target multiple neurotransmitter systems including serotonin to address this complexity.
Q3. Which receptor mechanism best explains the weight gain commonly observed with
olanzapine (Zyprexa)?
A. Dopamine D2 receptor blockade in the striatum
B. Serotonin 5-HT2A receptor blockade in cortical regions
, C. Histamine H1 receptor blockade combined with muscarinic M3 receptor antagonism, which impairs
insulin secretion and increases appetite ✓
D. Alpha-1 adrenergic receptor blockade causing fluid retention
Correct Answer: C
Rationale: Olanzapine has high affinity for histamine H1 receptors (causing sedation and appetite stimulation) and
muscarinic M3 receptors on pancreatic beta cells (impairing glucose-stimulated insulin secretion and contributing to
metabolic syndrome). Together, these mechanisms drive significant weight gain and metabolic dysregulation.
Dopamine D2 blockade causes EPS. Serotonin 5-HT2A blockade improves negative symptoms and reduces EPS
risk. Alpha-1 blockade causes orthostatic hypotension. Understanding receptor binding profiles helps predict side
effects for all antipsychotics.
Q4. The PMHNP is reviewing the pharmacodynamics of buspirone (Buspar) with a patient. The
mechanism of action that distinguishes buspirone from benzodiazepines is:
A. Buspirone enhances GABA-A receptor chloride channel conductance
B. Buspirone is a partial agonist at serotonin 5-HT1A receptors and a weak D2 receptor antagonist — it
has no activity at GABA receptors and lacks abuse potential ✓
C. Buspirone blocks both serotonin and norepinephrine reuptake transporters
D. Buspirone directly inhibits cortisol synthesis to reduce anxiety
Correct Answer: B
Rationale: Buspirone's unique mechanism involves partial agonism at presynaptic serotonin 5-HT1A autoreceptors
(reducing serotonin release to modulate anxiety) and some D2 receptor antagonism. Unlike benzodiazepines,
buspirone has no GABA activity, no cross-tolerance with benzodiazepines, no abuse/dependence potential, no
sedation, and requires 2–4 weeks for full anxiolytic effect. It is preferred for patients with substance use history.
Option A describes benzodiazepines. Option C describes SNRIs. These distinctions are essential for appropriate
anxiolytic selection.
Q5. A patient taking a monoamine oxidase inhibitor (MAOI) for treatment-resistant depression
eats aged cheese at a restaurant. Which receptor/enzyme interaction explains the potentially
life-threatening hypertensive crisis that may follow?
A. Tyramine activates serotonin receptors, causing vasodilation and hypotension
B. Tyramine, normally metabolized by intestinal and hepatic MAO, accumulates when MAO is inhibited
and acts as an indirect sympathomimetic — releasing large amounts of norepinephrine from presynaptic
terminals causing severe hypertension ✓
C. MAOI inhibition of acetylcholinesterase causes acetylcholine excess and cholinergic crisis
D. Tyramine directly stimulates dopamine D1 receptors causing cerebral vasoconstriction
Correct Answer: B
Rationale: Tyramine (present in aged cheeses, cured meats, fermented foods) is normally degraded by monoamine
oxidase (MAO-A) in the gut and liver. When MAO is inhibited by an MAOI, tyramine enters systemic circulation,
enters adrenergic neurons, and displaces norepinephrine from vesicular stores — flooding the synapse with
norepinephrine. This 'tyramine pressor response' can cause severe hypertensive crisis, potentially leading to
intracranial hemorrhage or stroke. PMHNPs must educate patients on strict dietary restrictions when prescribing
MAOIs (phenelzine, tranylcypromine, isocarboxazid) and the tyramine-free diet.
Q6. A PMHNP understands that the 'therapeutic window' concept is MOST clinically relevant
when managing which medication?
A. Sertraline (Zoloft) for major depressive disorder
B. Lithium for bipolar disorder — toxicity occurs just above therapeutic levels ✓
C. Alprazolam (Xanax) for panic disorder
D. Aripiprazole (Abilify) for schizophrenia
Correct Answer: B
Rationale: Lithium has one of the narrowest therapeutic windows in psychiatry — therapeutic serum levels are 0.6–
1.2 mEq/L (acute mania: up to 1.5 mEq/L), while toxicity begins near 1.5–2.0 mEq/L and becomes life-threatening
above 2.0 mEq/L. Toxic symptoms include coarse tremor, ataxia, confusion, seizures, cardiac arrhythmias, and renal
failure. Regular serum level monitoring is mandatory. SSRIs, benzodiazepines, and atypical antipsychotics have
, much wider safety margins and do not require the same intensity of plasma level monitoring. The narrow therapeutic
index requires PMHNPs to educate patients on hydration, sodium intake, and drug interactions.
Q7. Which neurotransmitter system is the PRIMARY target of medications used to treat
attention-deficit/hyperactivity disorder (ADHD)?
A. GABAergic system — stimulant medications enhance inhibitory neurotransmission
B. Catecholamine systems (dopamine and norepinephrine) in prefrontal cortex circuits — stimulants
increase dopamine and norepinephrine signaling, improving attention, working memory, and inhibitory
control ✓
C. Serotonergic system — SSRIs are the first-line treatment for ADHD
D. Cholinergic system — acetylcholinesterase inhibitors improve attention span
Correct Answer: B
Rationale: ADHD involves hypoactivation of prefrontal cortex (PFC) dopaminergic and noradrenergic circuits
responsible for executive function, working memory, and inhibitory control. Stimulants (methylphenidate,
amphetamines) primarily block dopamine/norepinephrine reuptake transporters (DAT/NET), increasing
catecholamine signaling in PFC. Non-stimulants for ADHD include atomoxetine (selective NET inhibitor), viloxazine
(NET reuptake inhibitor), guanfacine and clonidine (alpha-2A agonists — strengthen PFC connectivity). SSRIs and
cholinesterase inhibitors are not first-line ADHD treatments.
Q8. A patient on clozapine (Clozaril) for treatment-resistant schizophrenia is found
unresponsive with a temperature of 104°F, muscle rigidity, and altered consciousness. The
PMHNP recognizes this presentation as consistent with:
A. Serotonin syndrome — treat with cyproheptadine
B. Neuroleptic malignant syndrome (NMS) — a dopamine receptor blockade emergency requiring
immediate discontinuation of the antipsychotic and supportive care including dantrolene ✓
C. Anticholinergic toxidrome — treat with physostigmine
D. Malignant hyperthermia from anesthesia — treat with dantrolene and cooling
Correct Answer: B
Rationale: Neuroleptic Malignant Syndrome (NMS) is a rare but life-threatening idiosyncratic reaction to dopamine
antagonists (antipsychotics, metoclopramide). The classic tetrad is: hyperthermia, severe muscle rigidity (lead pipe
rigidity), autonomic instability (tachycardia, labile blood pressure, diaphoresis), and altered consciousness.
Laboratory findings include elevated CPK, leukocytosis, and myoglobinuria. Treatment: immediately discontinue the
offending agent, supportive care, dantrolene (muscle relaxant), bromocriptine (dopamine agonist). NMS differs from
serotonin syndrome (clonus, hyperreflexia, GI symptoms) and anticholinergic toxidrome (dry/flushed/hot, no rigidity).
Q9. A PMHNP is explaining the difference between 'tolerance' and 'dependence' to a patient
being prescribed a benzodiazepine. Which statement BEST reflects current pharmacological
understanding?
A. Tolerance and physical dependence are the same as addiction and indicate the patient has substance use
disorder
B. Tolerance (decreasing effect with repeated dosing) and physical dependence (physiological
adaptation requiring the drug to prevent withdrawal) can develop with prescribed benzodiazepines —
these are expected pharmacological phenomena distinct from addiction (compulsive use despite harm)
✓
C. Tolerance only develops with illicit benzodiazepines, not with prescribed doses
D. Physical dependence means the patient should abruptly stop the medication to prevent further dependence
Correct Answer: B
Rationale: Tolerance and physical dependence are expected pharmacological consequences of regular
benzodiazepine use at prescribed doses. Tolerance results from GABA-A receptor downregulation and decreased
sensitivity. Physical dependence means abrupt discontinuation causes withdrawal symptoms (anxiety, insomnia,
tremor, seizures — potentially life-threatening). These phenomena are distinct from addiction (SUD), which involves
compulsive drug-seeking behavior despite negative consequences. PMHNPs must educate patients clearly, taper
benzodiazepines slowly (10-25% per week) to prevent withdrawal seizures, and assess for SUD risk factors before
prescribing.
